To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A nationwide cohort study of inflammatory bowel disease, histological activity and fracture risk
Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg, Sweden; Department of Pediatrics, Queen Silvia Children's Hospital, Gothenburg, Sweden.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden; Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Inflammatory Bowel Disease Center at NYU Langone Health, Division of Gastroenterology, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.
Örebro University, School of Medical Sciences. Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.ORCID iD: 0000-0003-0122-7234
Show others and affiliations
2024 (English)In: Alimentary Pharmacology and Therapeutics, ISSN 0269-2813, E-ISSN 1365-2036, Vol. 60, no 11-12, p. 1549-1560Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Individuals with inflammatory bowel disease (IBD) are at increased risk of fracture. It is unclear if this risk varies by recent histological activity. AIMS: To determine the fracture risk in IBD during periods with and without histological inflammation.

METHODS: We studied a nationwide cohort of 54,591 individuals diagnosed with IBD in 1990-2016 with longitudinal data on ileo-colorectal biopsies. Fractures were identified by inpatient and hospital-based outpatient diagnoses. We derived Cox regression estimated hazard ratios (HRs) for fracture during 12 months following a histological inflammation (vs. histological remission) record after adjusting for socio-demographics, comorbidities, IBD duration, IBD-related surgery and hospitalization. We adjusted sensitivity analyses for medical IBD treatment including corticosteroids.

RESULTS: Mean age of patients was 44.0 (SD = 18.3) and 45.5 (SD = 17.1) years at biopsy with histological inflammation and remission, respectively. For histological inflammation, there were 1.37 (95% CI 1.29-1.46) fractures per 100 years' follow-up versus 1.31 (95% CI 1.19-1.44) for remission (adjusted [a]HR 1.12; 95% CI 1.00-1.26; p = 0.04). HRs were similar with histological inflammation of Crohn's disease (1.11; 95% CI 0.91-1.36) and ulcerative colitis (1.18; 95% CI 1.02-1.36). Estimates were consistent across age groups. An overall small excess risk of any fracture remained after accounting for corticosteroids. A more prominently raised fracture risk was observed in corticosteroid-naïve IBD patients with histological inflammation versus histological remission (aHR 1.41; 95% CI 1.07-1.85). The aHR of hip fracture following histological inflammation was 1.29 (95% CI 0.87-1.92).

CONCLUSIONS: Histological inflammation in IBD predicted a small increase in short-term fracture risk. Measures to reduce disease activity may reduce fracture risk in IBD.

Place, publisher, year, edition, pages
John Wiley & Sons, 2024. Vol. 60, no 11-12, p. 1549-1560
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-116245DOI: 10.1111/apt.18275ISI: 001318544800001PubMedID: 39308339Scopus ID: 2-s2.0-85204613437OAI: oai:DiVA.org:oru-116245DiVA, id: diva2:1900525
Funder
Swedish Research Council, 2020-01980; 2020-02002Swedish Society for Medical Research (SSMF), 935346; 935415; 935418University of GothenburgKarolinska InstituteRegion Stockholm, RS2021-0855
Note

This work was supported by the University of Gothenburg (KM), ALF-funding from Region Västra Götaland (KM), The Swedish Research Council (Dnr 2020-01980 to KM; Dnr: 2020-02002 to OO), The Swedish Society of Medicine (SLS-935346/935415/935418 to KM), Karolinska Institutet (JFL), Region Stockholm (Dnr: RS2021-0855 to OO), Crohn's and Colitis Foundation (JA), the Judith Stewart Colton Center for Autoimmunity (JA) and the NIH NIDDK Diseases (K23DK124570 to JA). 

Available from: 2024-09-24 Created: 2024-09-24 Last updated: 2025-02-11Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Halfvarson, JonasLudvigsson, Jonas F.

Search in DiVA

By author/editor
Halfvarson, JonasLudvigsson, Jonas F.
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
Alimentary Pharmacology and Therapeutics
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 29 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf